Skip to main content
. 2020 Feb 4;112(9):902–912. doi: 10.1093/jnci/djaa017

Table 2.

Patient characteristics in the CRYSTAL trial (NCT00154102)*

Patient characteristics LM mCRC patients with liver metastases SD quality
Cohorts CRC-FCSD and CRC-FSD
No. (%)
HQ quality
Cohort CRC-FCHQ-FC
Cohort CRC-FHQ FOLFIRI
Training No. (%) Validation No. (%) Training No. (%) Validation No. (%)
Patients, no. 78 38 78 51 288
Gender
 Male 50 (64.1) 29 (76.3) 51 (64.1) 31 (60.8) 184 (63.9)
 Female 28 (35.9) 9 (23.7) 27 (34.6) 20 (39.2) 104 (36.1)
Primary site
 Right colon 20 (25.6) 14 (36.8) 20 (25.6) 17 (33.3) 70 (24.3)
 Left colon 58 (74.4) 24 (63.2) 58 (74.4) 34 (66.7) 217 (75.3)
Prior adjuvant chemotherapy
 Yes 9 (11.5) 6 (15.8) 10 (12.8) 6 (11.8) 40 (13.9)
 No 69 (88.5) 32 (84.2) 68 (87.2) 45 (88.2) 248 (86.1)
Leucocytes
 Low 65 (83.3) 35 (92.1) 65 (83.3) 34 (66.7) 234 (81.3)
 High 12 (15.4) 3 (7.9) 10 (12.8) 15 (29.4) 45 (15.6)
LDH baseline
 Low 41 (52.6) 18 (47.4) 28 (35.9) 21 (41.2) 147 (51.0)
 High 29 (37.2) 15 (39.5) 36 (46.2) 21 (41.2) 111 (38.5)
 Unknown 8 (10.3) 5 (13.2) 14 (17.9) 9 (17.6) 30 (10.4)
Maximum staining intensity
 Low 13 (16.7) 1 (2.6) 12 (15.4) 7 (13.7) 48 (16.7)
 High 65 (83.3) 37 (97.4) 65 (83.3) 44 (86.3) 238 (82.6)
Histology of primary tumor
 Adenocarcinoma 72 (92.3) 35 (92.1) 76 (97.4) 50 (98.0) 283 (98.3)
 Mucinous adenocarcinoma 6 (7.7) 3 (7.9) 2 (2.6) 1 (2.0) 5 (1.7)
Histological differentiation
 Well differentiated 10 (12.8) 4 (10.5) 15 (19.2) 7 (13.7) 33 (11.5)
 Moderately differentiated 51 (65.4) 24 (63.2) 50 (64.1) 33 (64.7) 191 (66.3)
 Poorly differentiated 15 (19.2) 6 (15.8) 12 (15.4) 8 (15.7) 44 (15.3)
KRAS BRAF mutation status
 KRAS mutant 25 (32.1) 19 (50.0) 26 (33.3) 17 (33.3) 75 (26.0)
 KRAS and BRAF WT 50 (64.1) 15 (39.5) 46 (59.0) 31 (60.8) 129 (44.8)
 BRAF mutant 3 (3.8) 4 (10.5) 6 (7.7) 3 (5.9) 8 (2.8)
 Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 76 (26.4)
Target lesions at baseline, no.
 0 0 (0.0) 1 (2.6) 0 (0.0) 1 (2.0) 2 (0.7)
 1 5 (6.4) 5 (13.2) 12 (15.4) 3 (5.9) 31 (10.8)
 2 9 (11.5) 10 (26.3) 13 (16.7) 11 (21.6) 45 (15.6)
 3 14 (17.9) 7 (18.5) 18 (23.1) 11 (21.6) 44 (15.3)
 4 13 (16.7) 4 (10.5) 5 (6.4) 6 (11.8) 43 (14.9)
 5 24 (30.8) 7 (18.5) 16 (20.5) 10 (19.6) 70 (24.3)
 >5 14 (17.9) 4 (10.5) 14 (17.9) 10 (19.6) 53 (18.4)
Nontarget lesions at baseline, no.
 0 17 (21.8) 16 (42.1) 20 (25.6) 16 (31.4) 77 (26.7)
 1 35 (44.9) 8 (21.1) 25 (32.1) 16 (31.4) 90 (31.3)
 2 10 (12.8) 4 (10.5) 22 (28.2) 11 (21.6) 50 (17.4)
 3 6 (7.7) 6 (15.8) 6 (7.7) 4 (7.8) 19 (6.6)
 4 2 (2.6) 1 (2.6) 2 (2.6) 1 (2.0) 13 (4.5)
 5 4 (5.1) 2 (5.3) 2 (2.6) 1 (2.0) 18 (6.3)
 >5 4 (5.1) 1 (2.6) 1 (1.3) 2 (3.9) 21 (7.3)
Only liver metastasis 57 (73.1) 27 (71.1) 49 (62.8) 37 (72.5) 211 (73.3)
Only liver and lung metastasis 63 (80.8) 33 (86.8) 73 (93.6) 45 (88.2) 253 (87.8)
*

Liver metastatic patients included in the HQ cohorts have similar characteristics. The only difference is the quality of the CT scan acquisition protocol and reconstruction settings. The distribution of clinical characteristics for each subgroup of patients was compared using analysis of variance and χ2 (P values) and did not demonstrate any statistically significant difference between the cohorts. CT = computed tomography; CRC = colorectal cancer; F = FOLFIRI; FC = FOLFIRI+cetuximab; HQ = High computed tomography quality; SD = Standard computed tomography quality.